The treatment of hidradenitis suppurativa with the glucagon-like peptide -1 agonist liraglutide

Abstract

Hidradenitis suppurativa (HS) is a cutaneous disease associated with systemic inflammation, obesity and metabolic syndrome. Effective treatment options are limited. The anti-diabetic agents, incretins, have been used successfully to treat psoriasis – a disease also associated with metabolic syndrome. We report the use of liraglutide, a glucagon-like peptide -1 agonist, in a patient with HS, leading to subsequent weight loss and improvement in disease control. To our knowledge, this is the first report of liraglutide used in the treatment of HS.

This article is protected by copyright. All rights reserved.

http://ift.tt/2gyNG9s